Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Input: Consider Input: Not applicable. It’s understandable that costs wouldn’t be discussed at this early stage of research. Adequate explanation of results observed in study participants at different dosing levels. More importantly, the story simply explained: “Since it’s not completely clear what reductions in brain plaques mean for Alzheimer’s patients, the researchers are unable to say whether treatment with gantenerumab will bring improvement to patients with Alzheimer’s. They are currently involved in a new study that they hope will answer that question.” Better than its HealthDay competition in that WebMD actually told us how many people experienced harms in the study. The story allowed a Roche senior VP to say the results “went beyond our expectations” but countered that with “What is not entirely known is if these plaques cause Alzheimer’s…Therefore, it’s not known if reducing the amount of them will slow or stop the disease.” No disease mongering at play here. The story added an important independent perspective and identified the study co-author as being a senior VP of the drug company making the drug. We preferred how HealthDay explained:  “There are approximately one dozen therapies, including vaccines, that are currently in the pipeline….none are ready for prime time.” The story ends with an appropriate send-off:  “We need more studies to know if it is safe or effective.”  The early, experimental nature of the research is clear. The HealthDay competitor did a better job of explaining where this study fits in the history of research into beta-amyloid. There was clear evidence of independent reporting.

Output: Drug May Reduce Plaque in Brains of Alzheimer’s Patients


Input: Consider Input: The country went into a 21-day lockdown on Wednesday, and experts have said it faces a tidal wave of infections if rigorous steps are not taken to keep the virus in check. India’s public health care infrastructure is poor and it suffers from an acute shortage of medical staff, who will generally see many patients over a short period. Some doctors in temporary residences had been forcefully evicted by their landlords over infection fears, the Resident Doctor’s Association of the All India Institute of Medical Sciences (AIIMS) in New Delhi said. “(They) are now stranded on the roads with all their luggage, nowhere to go, across the country,” the association - which represents 2,500 doctors - said in a letter to the federal home minister on Tuesday, urging the government to intervene. Late on Tuesday India’s Health Minister Harsh Vardhan, himself a doctor, said on Twitter he was “deeply anguished” to see reports of doctors being ostracized in residential complexes, adding that precautions were being taken to ensure health care workers were not carriers of the infection. A home ministry spokeswoman said the Delhi state administration had issued orders saying penal action would be taken against those evicting doctors. She did not comment on the situation in other states. India, a country of 1.3 billion, has recorded 539 confirmed cases of COVID-19 and nine deaths. It has just one doctor for every 1,404 people, the government said in February, significantly below the World Health Organization’s norm of one per 1,000. The AIIMS association’s president, Adarsh Pratap Singh, said three doctors in New Delhi and around 15 in the southern city of Hyderabad had already faced issues with their accommodation. He did not have estimates of how many have been impacted overall. “People are not accepting them... The morale of doctors is down because of this, a stigma is being created due to lack of awareness of coronavirus,” he told Reuters on Wednesday. Airline staff have faced similar problems, with state-run carrier Air India and private airline IndiGo saying there had been instances of employees being ostracized from their communities.

Output: Indian doctors evicted over coronavirus transmission fears: medical body.


Input: Consider Input: Chief Executive Andrew Witty said on Wednesday there were still “intriguing” opportunities for its heart drug darapladib and MAGE-A3 therapeutic cancer vaccine. Many analysts stripped out forecasts for darapladib, which is designed to prevent heart attacks and strokes in a completely different way from cholesterol-lowering drugs, after it failed to reduce risks in the first of two big final Phase III trials in November. GSK, however, is continuing to investigate the drug’s role in coronary heart disease and Witty told analysts in a call following full-year results that further data on the approach would be presented at a medical meeting next month. He was also upbeat about prospects for the MAGE-A3 cancer vaccine in other tumor settings, despite initial negative results in melanoma in September. Unlike traditional preventative vaccines, MAGE-A3 is designed for people with established disease, helping their immune systems to prevent the return of tumors after surgery. In fact the head of Britain’s biggest drugmaker said both darapladib and MAGE-3 were among the most promising drugs in the company’s pipeline. He also highlighted a new triple combination respiratory drug, a long-acting integrase inhibitor for HIV and a drug for pre-term labor, all of which could start final Phase III clinical testing this year or next.


Output: GSK upbeat on heart drug, cancer vaccine despite setbacks.